The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes
- Author:
Evan SHLOFMITZ
1
;
Richard SHLOFMITZ
;
Michael S LEE
Author Information
- Publication Type:Review
- Keywords: Antiplatelet therapy; Oral anticoagulant; Non-vitamin K antagonist oral anticoagulants; Percutaneous coronary intervention
- MeSH: Anticoagulants; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Risk Assessment; Stents; Stroke; Thrombosis
- From:Korean Circulation Journal 2019;49(8):645-656
- CountryRepublic of Korea
- Language:English
- Abstract: The number of patients undergoing percutaneous coronary intervention (PCI) who mandate additional oral anticoagulant therapy has been increasing. Dual antiplatelet therapy (DAPT) is associated with reduced ischemic events including stent thrombosis, myocardial infarction and stroke following PCI. However, the tradeoff is an increased risk for bleeding while on DAPT. The addition of a novel oral anticoagulant (NOAC) further increases the likelihood of bleeding while on antiplatelet therapy. Thus, the overall risks and benefits for each patient undergoing PCI on NOAC must be assessed and therapy individualized to ensure optimal therapy for each unique situation. Patients on NOAC undergoing PCI should undergo routine assessment with intravascular imaging as the role of high-risk lesion-related features have increased importance prior to determining optimal duration of treatment with DAPT. We review the best practices for the pharmacologic management of patients requiring anticoagulation with NOAC who are treated with PCI and require antiplatelet therapy.
